Hairy Cell Leukemia drugs in development by stages, target, MoA, RoA, molecule type and key players, 2023

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued products.

GlobalData tracks 29 drugs in development for Hairy Cell Leukemia by 23 companies/universities/institutes. The top development phase for Hairy Cell Leukemia is phase ii with 13 drugs in that stage. The Hairy Cell Leukemia pipeline has 24 drugs in development by companies and five by universities/ institutes. Some of the companies in the Hairy Cell Leukemia pipeline products market are: F. Hoffmann-La Roche, Novartis and Wuhan Bio-Raid Biotechnology.

The key targets in the Hairy Cell Leukemia pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22), and Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1).

The key mechanisms of action in the Hairy Cell Leukemia pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with seven drugs in Phase II. The Hairy Cell Leukemia pipeline products include five routes of administration with the top ROA being Oral and seven key molecule types in the Hairy Cell Leukemia pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.

Hairy Cell Leukemia overview

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness, and weight loss. Risk factors include exposure to radiation, chemicals, and saw dust. Treatment includes surgery, chemotherapy, and radiation therapy.

For a complete picture of Hairy Cell Leukemia’s pipeline drug market, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.